Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LSMXE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2019126691A1 Conjugate No.62
|
|||||
| Synonyms |
Example 12
Click to Show/Hide
|
|||||
| Organization |
MERSANA THERAPEUTICS, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
Rituximab
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD20 (MS4A1)
|
Antigen Info | ||||
| Payload Name |
Conjugate No.60 Payload
|
Payload Info | ||||
| Linker Name |
Conjugate No.5 Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 1.37 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
HT29 cells were plated at a density of 5000 cells per well and the next day were treated with antibody-PBD conjugate for 3 days.
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 1.72 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
DLD1 cells were plated at a density of 5000 cells per well and the next day were treated with antibody-PBD conjugate for 3 days.
|
||||
| In Vitro Model | Colon adenocarcinoma | DLD1 cells | CVCL_0248 | ||